What is claimed is:

1. A cell formulation for subcutaneous administration comprising:

a. modified lymphocytes and/or tumor infiltrating lymphocytes and wherein the cell formulation further comprises a recombinant hyaluronidase, or

b. modified lymphocytes and neutrophils, wherein at least 10% of the cells in the cell formulation are neutrophils.

2. The cell formulation of claim 1, wherein the cell formulation comprises the recombinant hyaluronidase, and wherein the volume of the cell formulation is between 2 and 1,000 ml.

3. The cell formulation of claim 2, wherein the concentration of the recombinant hyaluronidase is between 50 and 5,000 units/ml.

4. The cell formulation of claim 2, wherein the recombinant hyaluronidase is recombinant human hyaluronidase PH20.

5. The cell formulation of claim 2, wherein the cell formulation comprises T cells, and wherein at least 15% of the T cells in the cell formulation are genetically modified.

6. The cell formulation of claim 1, wherein the cell formulation comprises modified lymphocytes, and wherein the modified lymphocytes are derived from a peripheral blood sample.

7. The cell formulation of claim 1, wherein the modified lymphocytes are associated with a replication incompetent recombinant retroviral particle comprising a polynucleotide, or wherein the modified lymphocytes comprise a polynucleotide from a replication incompetent recombinant retroviral particle,

wherein the polynucleotide comprises one or more transcriptional units operatively linked to a promoter active in T cells and/or NK cells, and wherein at least one of the one or more transcriptional units encodes a polypeptide and/or inhibitory RNA.

8. The cell formulation of claim 7, wherein the one or more transcriptional units encode the polypeptide, and wherein the polypeptide is a chimeric antigen receptor, engineered T cell receptor, lymphoproliferative element, cytokine, or a cell tag.

9. The cell formulation of claim 7, wherein the replication incompetent recombinant retroviral particle further comprises an activation element on its surface.

10. The cell formulation of claim 7, wherein the replication incompetent recombinant retroviral particle is a lentiviral particle.

11. The cell formulation of claim 7, wherein:

a. at least 80% of the modified lymphocytes in the cell formulation do not express the polypeptide, and/or

b. at least 25% of the modified lymphocytes in the cell formulation comprise a recombinant viral reverse transcriptase or a recombinant viral integrase.

12. The cell formulation of claim 7, wherein the cell formulation comprises modified lymphocytes, and wherein at least 75% of the modified lymphocytes in the cell formulation do not have the polynucleotide stably integrated into their genomes.

13. The cell formulation of claim 1, wherein the modified lymphocytes comprise modified T cells and/or modified NK cells, wherein the cell formulation further comprises aggregates comprising modified T cells and/or modified NK cells that are at least 15 um in their smallest dimension, and wherein at least 10% of the cells in the cell formulation are aggregated.

14. The cell formulation of claim 1, wherein the modified lymphocytes comprise modified T cells and/or modified NK cells, and wherein the cell formulation comprises between 1×10^6 and 1×10^9 modified T cells and/or modified NK cells.

15. The cell formulation of claim 1, wherein cell formulation is contained within a subcutaneous delivery device.

16. The cell formulation of claim 1, wherein at least 60% of the cells are viable.

17. The cell formulation of claim 1, wherein the cell formulation further comprises up to 50 mg/ml albumin and less than 7% DMSO, wherein the pH is adjusted to between 6.5 to 8.0.

18. The cell formulation of claim 1, wherein the cell formulation further comprises:

a. between 0.5 and 6 mg/ml sodium chloride (NaCl),

b. between 0.5 and 6 mg/ml sodium gluconate ($C_6H_{11}NaO_7$),

c. between 0.3 and 4 mg of sodium acetate trihydrate ($C_2H_3NaO_2 \cdot 3H_2O$),

d. between 0.3 and 4.5 mg/ml potassium chloride (KCl), and

e. between 0.03 to 0.4 mg/ml magnesium chloride ($MgCl_2 \cdot 6H_2O$).

19. Use of a replication incompetent recombinant retroviral particle in the manufacture of a kit for administering modified T cells and/or NK cells to a subject, comprising:

a. contacting T cells and/or NK cells ex vivo with replication incompetent recombinant retroviral particles comprising a polynucleotide encoding a transgene, wherein the recombinant retroviral particles modify the T cells and/or NK cells;

b. collecting the modified T cells and/or NK cells to form a cell formulation comprising a suspension of the modified T cells and/or NK cells; and

c. administering the cell formulation to a subject subcutaneously,

wherein at least 25% of the modified T cells and/or NK cells in the cell formulation do not have the polynucleotide stably integrated into their genomes.

20. The use of claim 19, wherein the use further comprises collecting a peripheral blood sample, and wherein the cell formulation comprises monocytes, wherein at least 10% of the monocytes present in the blood sample are present in the cell formulation.